CGS 15943 is a novel, potent and selective adenosine receptor antagonist with Ki values of 3.5, 4.2, 16 and 51 nM for human A1, A2A, A2B and A3 receptors respectively.

Physicochemical Properties

Molecular Formula	C13H8CLN5O
Molecular Weight	285.68852
Exact Mass	285.042
CAS #	104615-18-1
PubChem CID	2690
Appearance	White to off-white solid powder
Density	1.72 g/cm3
Boiling Point	566.6ºC at 760 mmHg
Melting Point	278-279 °C
Flash Point	296.5ºC
Vapour Pressure	7.4E-13mmHg at 25°C
Index of Refraction	1.84
LogP	3.354
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	5
Rotatable Bond Count	1
Heavy Atom Count	20
Complexity	373
Defined Atom Stereocenter Count	0
InChi Key	MSJODEOZODDVGW-UHFFFAOYSA-N
InChi Code	InChI=1S/C13H8ClN5O/c14-7-3-4-9-8(6-7)12-17-11(10-2-1-5-20-10)18-19(12)13(15)16-9/h1-6H,(H2,15,16)
Chemical Name	9-chloro-2-furan-2-yl-[1,2,4]triazolo[1,5-c]quinazolin-5-amine
Synonyms	CGS 15943 CGS15943 CGS-15943.
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vitro	CGS 15943 slightly inhibits p110δ with an IC50 of 8.47 μM and suppresses the intermittent activity of class IB PI3K isoform p110γ with an IC50 of 1.1 μM [3]. HLF and SK-Hep are inhibited by CGS 15943 (0–20 μM; 72 hours). CGS 15943 (0 -20 μM; 24 hours) inhibits the development of HepG2 and PLC-PRF-5 cells [3] as well as the phosphorylation of Akt residues Ser473 and Thr308 in HLF and Sk-Hep-1 cells [3].
Cell Assay	Cell viability assay [3] Cell Types: HLF, SK-Hep-1, HepG2 and PLC-PRF-5 Cell Tested Concentrations: 0 μM; ]. 1μM; 5μM; 10μM; 20 μM Incubation Duration: 24 hrs (hours) Experimental Results: Inhibited the growth of four different HCC cell lines. Western Blot Analysis[3] Cell Types: HLF and Sk-Hep-1 cells Tested Concentrations: 0 μM; 1μM; 5μM; 10μM; 20 μM Incubation Duration: 24 hrs (hours) Experimental Results: Inhibition of PI3K/ in HLF and Sk-Hep-1 cells Akt pathway
References	[1]. CGS 15943, an adenosine A2 receptor antagonist, reduces cerebral ischemic injury in the Mongolian gerbil. Life Sci. 1994;55(3):PL61-5. [2]. Adenosine receptors and their ligands. Naunyn Schmiedebergs Arch Pharmacol. 2000 Nov;362(4-5):382-91. [3]. Caffeine and the analog CGS 15943 inhibit cancer cell growth by targeting the phosphoinositide 3-kinase/Akt pathway. Cancer Biol Ther. 2014 May;15(5):524-32.
Additional Infomation	CGS 15943 is a member of the class of triazoloquinazolines that is [1,2,4]triazolo[1,5-c]quinazoline substited at positions 2, 5 and 9 by furan-2-yl, amino and chloro groups respectively. A potent antagonist at adenosine A1 and adenosine A2A receptors. It has a role as an adenosine A1 receptor antagonist, an adenosine A2A receptor antagonist, a central nervous system stimulant and an antineoplastic agent. It is a triazoloquinazoline, an organochlorine compound, a member of furans, a biaryl, an aromatic amine and a primary amino compound.

Solubility Data

Solubility (In Vitro)

DMSO : ~12.22 mg/mL (~42.77 mM)

Solubility (In Vivo)

Solubility in Formulation 1: 1.22 mg/mL (4.27 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.2 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 1.22 mg/mL (4.27 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.2 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 1.22 mg/mL (4.27 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.2 mg/mL clear DMSO stock solution to 900 μL corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	3.5003 mL	17.5015 mL	35.0030 mL
	5 mM	0.7001 mL	3.5003 mL	7.0006 mL
	10 mM	0.3500 mL	1.7501 mL	3.5003 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.